Cytosorbents (CTSO) Set to Announce Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) is expected to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($0.90) per share and revenue of $9.90 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Cytosorbents Trading Down 0.5%

Shares of Cytosorbents stock opened at $5.80 on Wednesday. Cytosorbents has a 12-month low of $2.84 and a 12-month high of $17.00. The company has a market cap of $18.27 million, a price-to-earnings ratio of -1.00 and a beta of 1.49. The company has a current ratio of 0.66, a quick ratio of 0.50 and a debt-to-equity ratio of 4.70. The company’s 50-day moving average price is $4.99 and its 200-day moving average price is $9.20.

Wall Street Analysts Forecast Growth

CTSO has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, October 2nd. WBB Securities began coverage on shares of Cytosorbents in a report on Wednesday, October 21st. They issued a “speculative buy” rating and a $9.50 price target for the company. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $74.83.

Insider Transactions at Cytosorbents

In related news, CEO Phillip Chan bought 200,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was bought at an average cost of $0.35 per share, for a total transaction of $70,000.00. Following the completion of the transaction, the chief executive officer owned 1,944,432 shares of the company’s stock, valued at approximately $680,551.20. The trade was a 11.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 7.80% of the company’s stock.

Cytosorbents Company Profile

CytoSorbents Corporation is a medical device and healthcare company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent materials that can bind and remove cytokines, inflammatory mediators, drugs, and other molecules during extracorporeal blood treatment. The company’s principal product is CytoSorb, an extracorporeal cytokine adsorber used in critical care and cardiac surgery applications.